CCCC Q3 2024 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+38.7% YoY

Gross Profit

$13M86.6% margin

Operating Income

-$28M-183.9% margin

Net Income

-$25M-160.6% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+28.0%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$376M

Total Liabilities

$133M

Stockholders' Equity

$243M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$11M	+38.7%
Gross Profit	$13M	$9M	+46.6%
Operating Income	-$28M	-$28M	-1.6%
Net Income	-$25M	-$27M	+8.8%